JP2023527410A - 骨髄細胞炎症性表現型を調節するための抗ｖｓｉｇ４組成物及び方法、ならびにその使用 - Google Patents

骨髄細胞炎症性表現型を調節するための抗ｖｓｉｇ４組成物及び方法、ならびにその使用 Download PDF

Info

Publication number
JP2023527410A
JP2023527410A JP2022573201A JP2022573201A JP2023527410A JP 2023527410 A JP2023527410 A JP 2023527410A JP 2022573201 A JP2022573201 A JP 2022573201A JP 2022573201 A JP2022573201 A JP 2022573201A JP 2023527410 A JP2023527410 A JP 2023527410A
Authority
JP
Japan
Prior art keywords
cells
macrophages
antigen
cell
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022573201A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023527410A5 (enExample
Inventor
タティアナ アイ． ノボブラントセバ，
イゴール フェルドマン，
スティーブン エル． サジンスキー，
エリザベス クリバ，
フォン アン グエン，
マヤ ラズログ，
Original Assignee
ヴェルソー セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴェルソー セラピューティクス， インコーポレイテッド filed Critical ヴェルソー セラピューティクス， インコーポレイテッド
Publication of JP2023527410A publication Critical patent/JP2023527410A/ja
Publication of JP2023527410A5 publication Critical patent/JP2023527410A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hospice & Palliative Care (AREA)
JP2022573201A 2020-05-29 2021-05-28 骨髄細胞炎症性表現型を調節するための抗ｖｓｉｇ４組成物及び方法、ならびにその使用 Pending JP2023527410A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063032337P 2020-05-29 2020-05-29
US63/032,337 2020-05-29
PCT/US2021/034784 WO2021243169A1 (en) 2020-05-29 2021-05-28 Anti-vsig4 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof

Publications (2)

Publication Number Publication Date
JP2023527410A true JP2023527410A (ja) 2023-06-28
JP2023527410A5 JP2023527410A5 (enExample) 2024-06-05

Family

ID=78722851

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022573201A Pending JP2023527410A (ja) 2020-05-29 2021-05-28 骨髄細胞炎症性表現型を調節するための抗ｖｓｉｇ４組成物及び方法、ならびにその使用

Country Status (11)

Country Link
US (1) US20230348603A1 (enExample)
EP (1) EP4157886A4 (enExample)
JP (1) JP2023527410A (enExample)
KR (1) KR20230017778A (enExample)
CN (1) CN115996953A (enExample)
AU (1) AU2021281356A1 (enExample)
BR (1) BR112022023892A2 (enExample)
CA (1) CA3182814A1 (enExample)
IL (1) IL298545A (enExample)
TW (1) TW202210523A (enExample)
WO (1) WO2021243169A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025037646A1 (ja) * 2023-08-17 2025-02-20 国立大学法人東京大学 ＶＳＩＧ４とＳｉｇｌｅｃ－７との分子間相互作用に対する抗ＶＳＩＧ４、抗Ｓｉｇｌｅｃ－７阻害抗体
WO2025095548A1 (ko) * 2023-10-31 2025-05-08 인제대학교 산학협력단 신장 이식 후 만성거부반응 진단용 조성물

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240392037A1 (en) * 2022-01-10 2024-11-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Molecules that bind to neutrophil elastase polypeptides
KR20240058017A (ko) * 2022-10-21 2024-05-03 주식회사 유틸렉스 항-vsig4 항체를 포함하는 항암용 조성물
CN116380755B (zh) * 2023-03-20 2023-11-21 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） CD127+PMN-MDSCs在诊断支气管肺发育不良中的应用及诊断试剂盒

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008130204A1 (en) * 2007-04-24 2008-10-30 Eucell Bio Co., Ltd. New anti-irc85 monoclonal antibody; and composition comprising the same for preventing and treating tuberculosis or enteritis disease; and the use thereof
WO2019005817A2 (en) * 2017-06-26 2019-01-03 Bio-Techne Corporation HYBRIDOMIC CLONES, MONOCLONAL ANTIBODIES DIRECTED AGAINST VSIG-4, AND METHODS OF MAKING AND USING SAME
WO2020069507A1 (en) * 2018-09-28 2020-04-02 Eutilex Co., Ltd. Anti-human vsig4 antibodies and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009319864A1 (en) * 2008-11-25 2011-07-14 Biogen Idec Ma Inc. Use of DR6 and P75 antagonists to promote survival of cells of the nervous system
CN102459335B (zh) * 2009-04-17 2015-11-25 伊缪纳斯制药株式会社 特异性结合Aβ寡聚体的抗体及其用途
KR101730868B1 (ko) * 2013-09-13 2017-04-27 인제대학교 산학협력단 Ｖｓｉｇ４ 억제제를 유효성분으로 포함하는 난소암 예방 또는 치료용 약학조성물
CN105924515B (zh) * 2016-04-25 2019-06-14 中国人民解放军第三军医大学 免疫共刺激分子vsig4激活性表位肽、单克隆抗体及其制备方法和应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008130204A1 (en) * 2007-04-24 2008-10-30 Eucell Bio Co., Ltd. New anti-irc85 monoclonal antibody; and composition comprising the same for preventing and treating tuberculosis or enteritis disease; and the use thereof
WO2019005817A2 (en) * 2017-06-26 2019-01-03 Bio-Techne Corporation HYBRIDOMIC CLONES, MONOCLONAL ANTIBODIES DIRECTED AGAINST VSIG-4, AND METHODS OF MAKING AND USING SAME
WO2020069507A1 (en) * 2018-09-28 2020-04-02 Eutilex Co., Ltd. Anti-human vsig4 antibodies and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FRONTIERS IN IMMUNOLOGY, vol. 10, JPN6025022464, 2019, pages 2892 - 1, ISSN: 0005771732 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025037646A1 (ja) * 2023-08-17 2025-02-20 国立大学法人東京大学 ＶＳＩＧ４とＳｉｇｌｅｃ－７との分子間相互作用に対する抗ＶＳＩＧ４、抗Ｓｉｇｌｅｃ－７阻害抗体
WO2025095548A1 (ko) * 2023-10-31 2025-05-08 인제대학교 산학협력단 신장 이식 후 만성거부반응 진단용 조성물

Also Published As

Publication number Publication date
EP4157886A4 (en) 2024-10-16
TW202210523A (zh) 2022-03-16
WO2021243169A1 (en) 2021-12-02
EP4157886A1 (en) 2023-04-05
IL298545A (en) 2023-01-01
CA3182814A1 (en) 2021-12-02
BR112022023892A2 (pt) 2022-12-27
AU2021281356A1 (en) 2023-01-19
CN115996953A (zh) 2023-04-21
KR20230017778A (ko) 2023-02-06
US20230348603A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
JP7716992B2 (ja) 骨髄細胞炎症性表現型を調節するための抗ｐｓｇｌ－１組成物及び方法、ならびにその使用
US20220396627A1 (en) Anti-siglec-9 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
EP3204422B1 (en) Humanized anti-ox40 antibodies and uses thereof
TWI718118B (zh) 針對ｒｏｒ１之特異性抗體及嵌合抗原受體
JP2023527410A (ja) 骨髄細胞炎症性表現型を調節するための抗ｖｓｉｇ４組成物及び方法、ならびにその使用
US20220251233A1 (en) Anti-cd53 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
JP2021520208A (ja) Ｈｈｌａ２受容体としてのｋｉｒ３ｄｌ３、抗ｈｈｌａ２抗体、およびその使用
US20220363752A1 (en) Anti-lrrc25 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240528

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250602

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260413